Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
暂无分享,去创建一个
[1] Jaegyun Lim,et al. Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR , 2020, Journal of Korean medical science.
[2] Jiyuan Zhang,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.
[3] G. Banna,et al. Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients. , 2020, Immunotherapy.
[4] F. Mazzoni,et al. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. , 2018, Immunotherapy.
[5] Yan Bai,et al. Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.
[6] H. Rothan,et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.
[7] N. Ramaiya,et al. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.
[8] D. Leino,et al. Severe cytokine release syndrome in a patient receiving PD‐1‐directed therapy , 2017, Pediatric blood & cancer.
[9] Weifeng He,et al. [Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies]. , 2020, Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns.
[10] L. Shen,et al. Response to “Comments on 'Zhang et al: Clinical trial analysis of 2019‐nCoV therapy registered in China'” , 2020, Journal of medical virology.
[11] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[12] Huahao Shen,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[13] P. Taylor,et al. Interleukin‐6 limits influenza‐induced inflammation and protects against fatal lung pathology , 2013, European journal of immunology.
[14] Rede de Informação e Conhecimento. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) , 2020 .
[15] N. Sharma,et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[16] S. Buti,et al. From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis , 2017, World journal of clinical oncology.
[17] In Italia,et al. Associazione Italiana di Oncologia Medica , 1997 .
[18] L. Shen,et al. Clinical trial analysis of 2019‐nCoV therapy registered in China , 2020, Journal of medical virology.
[19] M. Koopmans,et al. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. , 2020, The New England journal of medicine.
[20] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[21] Li Zhang,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[22] S. Buti,et al. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. , 2019, Seminars in oncology.
[23] Xiaohu Zheng,et al. Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.
[24] G. Coukos,et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy , 2018, Journal of Immunotherapy for Cancer.
[25] J. Teijaro. The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options. , 2015, Current topics in microbiology and immunology.
[26] S. Lee,et al. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors , 2020, Immune network.
[27] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.